Shots:

• The P-II/III BLAZE-1 trial involves assessing of Bamlanivimab + Etesevimab (2800 mg) vs PBO in 1035 patients recently diagnosed with COVID-19 in the ambulatory setting
• The results demonstrated an 70% reduction in risk of COVID-19 related hospitalizations and deaths in high-risk patients and improvements in all 2EPs including reductions in viral load and accelerated symptom resolution
• The data from the BLAZE-1 study are both compelling and entirely consistent with the interim data that were the basis for EUA of bamlanivimab (700mg) in the US- Canada- and EU for mild to mod. COVID-19 in patients aged ≥12yrs. who are at high risk for progressing to severe COVID-19 or hospitalization

 ­ Ref: Businesswire | Image: Eli Lilly